The stock of Elevation Oncology Inc (ELEV) has gone up by 0.84% for the week, with a -45.45% drop in the past month and a -53.46% drop in the past quarter. The volatility ratio for the week is 10.62%, and the volatility levels for the past 30 days are 11.11% for ELEV. The simple moving average for the past 20 days is -31.26% for ELEV’s stock, with a -72.67% simple moving average for the past 200 days.
Is It Worth Investing in Elevation Oncology Inc (NASDAQ: ELEV) Right Now?
Additionally, the 36-month beta value for ELEV is 1.67. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for ELEV is 52.06M and currently, short sellers hold a 16.81% ratio of that float. The average trading volume of ELEV on April 02, 2025 was 2.60M shares.
ELEV) stock’s latest price update
Elevation Oncology Inc (NASDAQ: ELEV)’s stock price has plunge by 7.19relation to previous closing price of 0.25. Nevertheless, the company has seen a 0.84% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-25 that — Abstract accepted for late-breaking poster presentation – — EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers — — On-track to file an Investigational New Drug (IND) application in 2026 – BOSTON, March 25, 2025 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois. EO-1022 is an antibody drug conjugate (ADC) containing seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody (mAb), which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4.
Analysts’ Opinion of ELEV
Many brokerage firms have already submitted their reports for ELEV stocks, with Stephens repeating the rating for ELEV by listing it as a “Equal-Weight.” The predicted price for ELEV in the upcoming period, according to Stephens is $1 based on the research report published on March 24, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see ELEV reach a price target of $0.70. The rating they have provided for ELEV stocks is “Neutral” according to the report published on March 21st, 2025.
Leerink Partners gave a rating of “Market Perform” to ELEV, setting the target price at $1 in the report published on March 21st of the current year.
ELEV Trading at -49.21% from the 50-Day Moving Average
After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.45% of loss for the given period.
Volatility was left at 11.11%, however, over the last 30 days, the volatility rate increased by 10.62%, as shares sank -49.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -64.07% lower at present.
During the last 5 trading sessions, ELEV fell by -2.81%, which changed the moving average for the period of 200-days by -92.37% in comparison to the 20-day moving average, which settled at $0.3855. In addition, Elevation Oncology Inc saw -52.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ELEV
The total capital return value is set at -0.49. Equity return is now at value -77.48, with -48.17 for asset returns.
Based on Elevation Oncology Inc (ELEV), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -1.17. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is -71.18.
Currently, EBITDA for the company is -44.7 million with net debt to EBITDA at 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.21.
Conclusion
In conclusion, Elevation Oncology Inc (ELEV) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
